What Else?

Following discussions with the FDA, the company has decided to conduct a Phase 2 trial in breast cancer, supported by previously generated data from past studies. The company says this move is seen as a logical progression, considering the larger market for breast cancer compared to colorectal cancer.

The FDA and Processa believe that developing NGC-Cap for breast cancer will lead to a more efficient development program and increase the likelihood of FDA approval.

The Phase 2 trial aims to demonstrate the safety and efficacy of NGC-Cap over existing treatments, with plans to initiate the study in the third quarter of 2024.

See Also: Fed’s Goolsbee Expects Interest Rates To Fall With Inflation

According to data from Benzinga Pro, PCSA has a 52-week high of $1.27 and a 52-week low of $0.18.